HOSPIRA ISSUES A VOLUNTARY NATIONWIDE RECALL OF ONE LOT OF METOCLOPRAMIDE INJECTION, USP, AND TWO LOTS OF ONDANSETRON INJECTION, USP, DUE TO GLASS (GLASS STRANDS) PARTICULATES CAUSED BY GLASS SUPPLIER DEFECT

You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

HOSPIRA ISSUES A VOLUNTARY NATIONWIDE RECALL OF ONE LOT OF METOCLOPRAMIDE INJECTION, USP, AND TWO LOTS OF ONDANSETRON INJECTION, USP, DUE TO GLASS (GLASS STRANDS) PARTICULATES CAUSED BY GLASS SUPPLIER DEFECT

10/02/2013 10:25 AM EDT

Hospira, Inc. (NYSE: HSP), announced today it initiated a voluntary nationwide recall of one lot of Metoclopramide Injection, USP, 10 mg/2 mL (5 mg/mL), NDC 0409-3414-01, Lot 28-104-DK and two lots of Ondansetron Injection, USP, 4 mg/2 mL, (2 mg/mL), NDC 0409-4755-03, Lots 29-484-DK and 29-510-DK. This action is due to a confirmed vial defect where glass particulate matter (glass strands) were identified as being affixed to the inside of the vial walls. There is potential for the glass particulates to dislodge into the solution.

. For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, please click the link at the beginning of this bulletin.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? support@govdelivery.com
• Other inquiries? webmail@oc.fda.gov

---

This email was sent to filter@clubhouseb.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420